| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | 2-[(E)-[1-(2-Amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid;(2S)-2,6-diaminohexanoic acid | FAERS: 19 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 2 | ambrisentan | FAERS: 18 | US FAERS | |
| 3 | macitentan | FAERS: 16 | US FAERS | |
| 4 | Bosentan | FAERS: 6 | US FAERS | |
| 5 | Epoprostenol | FAERS: 2 | US FAERS | |
| 6 | carfilzomib | FAERS: 2 | US FAERS | |
| 7 | ledipasvir, sofosbuvir drug combination | FAERS: 2 | US FAERS | |
| 8 | Iloprost | FAERS: 1 | US FAERS | |
| 9 | Methotrexate | FAERS: 1 | US FAERS | |
| 10 | Naproxen | FAERS: 1 | US FAERS | |
| 11 | Sofosbuvir | FAERS: 1 | US FAERS | |
| 12 | ponatinib | FAERS: 1 | US FAERS | |
| 13 | selexipag | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.